Airway remodelling in asthma and the epithelium: on the edge of a new era
European Respiratory Journal · 2024-04 · 63 (4) · 2301619
DOI: 10.1183/13993003.01619-2023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Respiratory Journal, online erschienen am 12.04.2024. Verfasst von Gilda Varricchi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), School of Medicine, University of Naples F…. Hauptthemen laut MEDLINE: Airway Remodeling, Asthma. Die Arbeit wurde bisher 174-mal zitiert (Crossref) und nennt 189 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen, AstraZeneca.
Abstract (Originalsprache)
Asthma is a chronic, heterogeneous disease of the airways, often characterised by structural changes known collectively as airway remodelling. In response to environmental insults, including pathogens, allergens and pollutants, the epithelium can initiate remodelling via an inflammatory cascade involving a variety of mediators that have downstream effects on both structural and immune cells. These mediators include the epithelial cytokines thymic stromal lymphopoietin, interleukin (IL)-33 and IL-25, which facilitate airway remodelling through cross-talk between epithelial cells and fibroblasts, and between mast cells and airway smooth muscle cells, as well as through signalling with immune cells such as macrophages. The epithelium can also initiate airway remodelling independently of inflammation in response to the mechanical stress present during bronchoconstriction. Furthermore, genetic and epigenetic alterations to epithelial components are believed to influence remodelling. Here, we review recent advances in our understanding of the roles of the epithelium and epithelial cytokines in driving airway remodelling, facilitated by developments in genetic sequencing and imaging techniques. We also explore how new and existing therapeutics that target the epithelium and epithelial cytokines could modify airway remodelling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), School of Medicine, University of Naples Federico II, WAO Center of Excellence, Naples, Italy.
- Institute of Experimental Endocrinology and Oncology (IEOS), National Research Council, Naples, Italy.
- G. Varricchi and C.E. Brightling contributed equally.
- Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
- School of Medicine and Public Health, University of Newcastle, Callaghan, Australia ceb17@leicester.ac.uk.
- Center for Inflammation Research, Laboratory of Immunoregulation and Mucosal Immunology, VIB Center for Inflammation Research, Ghent, Belgium.
ORCID-Profile: Pascal Chanez
Förderung
- Amgen
- AstraZeneca
Zitieren
APA
Varricchi, G., Brightling, C. E., Grainge, C., Lambrecht, B. N., & Chanez, P. (2024). Airway remodelling in asthma and the epithelium: on the edge of a new era. European Respiratory Journal, 63(4), 2301619. https://doi.org/10.1183/13993003.01619-2023
Vancouver
Varricchi G, Brightling CE, Grainge C, Lambrecht BN, Chanez P. Airway remodelling in asthma and the epithelium: on the edge of a new era. European Respiratory Journal. 2024;63(4):2301619. doi:10.1183/13993003.01619-2023
BibTeX
@article{Varricchi2024,
author = {Varricchi, Gilda and Brightling, Christopher E and Grainge, Christopher and Lambrecht, Bart N and Chanez, Pascal},
title = {Airway remodelling in asthma and the epithelium: on the edge of a new era},
journal = {European Respiratory Journal},
year = {2024},
volume = {63},
number = {4},
pages = {2301619},
doi = {10.1183/13993003.01619-2023}
}
EUVIMED